Search research articles
Contact Us
Filters
Showing results (91-100 of 110) with videos related to
Page
of 11
Sort By:
Hepatology Communications
|
October 29, 2024
Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus
Jee-Fu Huang, Tien-Jyun Chang, Ming-Lun Yeh, et al.
The American Journal of Gastroenterology
|
March 30, 2020
Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
Chung-Feng Huang, Hsueh-Chou Lai, Chi-Yi Chen, et al.
Hepatology International
|
August 8, 2021
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
Ming-Lun Yeh, Chao-Hung Hung, Kuo-Chih Tseng, et al.
American Journal of Cancer Research
|
August 15, 2022
Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort study
Hung-Wei Wang, Pei-Chein Tsai, Chi-Yi Chen, et al.
Scientific Reports
|
March 28, 2020
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis
Wei-Fan Hsu, Chi-Yi Chen, Kuo-Chih Tseng, et al.
Journal of Gastroenterology and Hepatology
|
May 8, 2021
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)
Wei-Fan Hsu, Pei-Chein Tsai, Chi-Yi Chen, et al.
Journal of Hepatology
|
October 8, 2022
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan
Pei-Chien Tsai, Hsing-Tao Kuo, Chao-Hung Hung, et al.
Journal of Gastroenterology and Hepatology
|
February 24, 2021
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan
Meng-Hsuan Hsieh, Ming-Jong Bair, Pei-Chien Tsai, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
March 1, 2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program
Hung-Wei Wang, Yu-Syuan Zeng, Chung-Feng Huang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
June 10, 2025
Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)
Ping-Jen Hu, Ming-Lung Yu, Ming-Yao Chen, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 110) with videos related to
Sort By:
Page
of 11
Hepatology Communications
|
October 29, 2024
Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus
Jee-Fu Huang, Tien-Jyun Chang, Ming-Lun Yeh, et al.
The American Journal of Gastroenterology
|
March 30, 2020
Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
Chung-Feng Huang, Hsueh-Chou Lai, Chi-Yi Chen, et al.
Hepatology International
|
August 8, 2021
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
Ming-Lun Yeh, Chao-Hung Hung, Kuo-Chih Tseng, et al.
American Journal of Cancer Research
|
August 15, 2022
Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort study
Hung-Wei Wang, Pei-Chein Tsai, Chi-Yi Chen, et al.
Scientific Reports
|
March 28, 2020
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis
Wei-Fan Hsu, Chi-Yi Chen, Kuo-Chih Tseng, et al.
Journal of Gastroenterology and Hepatology
|
May 8, 2021
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)
Wei-Fan Hsu, Pei-Chein Tsai, Chi-Yi Chen, et al.
Journal of Hepatology
|
October 8, 2022
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan
Pei-Chien Tsai, Hsing-Tao Kuo, Chao-Hung Hung, et al.
Journal of Gastroenterology and Hepatology
|
February 24, 2021
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan
Meng-Hsuan Hsieh, Ming-Jong Bair, Pei-Chien Tsai, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
March 1, 2025
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program
Hung-Wei Wang, Yu-Syuan Zeng, Chung-Feng Huang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
June 10, 2025
Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)
Ping-Jen Hu, Ming-Lung Yu, Ming-Yao Chen, et al.
Page
of 11